Clinical trial
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast…
NCT00380835 · Celgene Corporation, Industry · Withdrawn
Key facts
| NCT number | NCT00380835 |
|---|---|
| Title | Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer |
| Official title | A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Amrubicin |
| Enrollment | 66 |
| Completion | Dec 1, 2007 |
| First posted | Sep 27, 2006 |
| Last update posted | Sep 23, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: